Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start a couple weeks ago), but we're grateful the sidewalk snowbanks are ...
Stopping GLP-1s can quickly reverse the cardiovascular benefits gained while taking them. Image Credit: the_burtons/Getty Images
A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide.
The findings show that stopping the medications for as little as 6 months raises the risk of heart attack and stroke.
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.
FRIDAY, March 20, 2026 — Drugs like Ozempic and Mounjaro are known to lower the risk of heart attack and stroke, but a new study suggests those benefits may not last if people stop taking them.Researchers found that heart risks begin to rise again w...
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
Stopping popular weight-loss injections like Ozempic or Mounjaro might not trigger the dramatic rebound many fear. A large real-world study of nearly 8,000 patients found that most people who discontinue these drugs manage to keep the weight off—or even continue losing—by restarting treatment, switching medications, or adopting lifestyle changes. While earlier clinical trials suggested rapid weight regain, this new evidence paints a more hopeful picture.
(MedPage Today) -- The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose -- three times the strength...
INDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational...
With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.